Review
Tocilizumab and anakinra in managing cytokine release syndrome after immunotherapy
After CAR-T-cell or bispecific antibody therapy, timely recognition of cytokine release syndrome and assessment of its severity are important. Management should account for severity grade and clinical manifestations.
#tocilizumab #anakinra d8miq7k9f04rm.cloudfront.net